Global Cyclooxygenase 2 Inhibitor Market, By Drug Type (Celecoxib, Rofecoxib, Valdecoxib, Amlodipine, Others), Types (Selective cox 2 inhibitor and Non-selective cox 2 inhibitor), Indication (Osteoarthritis, Rheumatoid arthritis and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to be one of the most widely used therapeutics owing to their anti-pyretic, analgesic and anti-inflammatory activities. Cyclooxygenase 2 Inhibitors refer to a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) that work by reducing the production of prostaglandins. Prostaglandins chemicals promote pain, inflammation and fever.
Cyclooxygenase 2 Inhibitors, or COX-2 inhibitors are used for treating conditions that cause inflammation, mild to moderate fever and pain. Data Bridge Market Research analyses that the cyclooxygenase 2 inhibitor market is estimated to grow at a CAGR of 10.50% during the forecast period of 2022 to 2029.
Cyclooxygenase 2 Inhibitor Market Dynamics
- Prevalence of Arthiritis
The increase in the prevalence of conditions that cause inflammation and pain, such as osteoarthritis, and rheumatoid arthritis across the globe acts as one of the major factor driving the growth of cyclooxygenase 2 inhibitor market.
- Increase In Mergers and Acquisitions
The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.
- Pain management
The high use of the cyclooxygenase 2 inhibitor, such as Celecoxib owing to its effectiveness as other NSAIDs (such as ibuprofen, diclofenac, and naproxen) at reducing pain and inflammation will assist in the expansion of the market.
- Financial support to the researchers for developing novel intervention
Various public and private organizations are increasing their investments in developing novel interventions and treatments that enhance the of cyclooxygenase 2 inhibitor market.
Additionally, increase in demand for effective therapies, development in technology, surge in healthcare expenditure, and large patient base and superior technology positively affect the cyclooxygenase 2 inhibitor market.
Furthermore, advancements in the product to reduce the associated side-effects extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, research and development will escalate the growth of cyclooxygenase 2 inhibitor market.
On the other hand, high cost associated with the inhibitors and limited availability are expected to obstruct the market growth. The concerns regarding the side-effects such as risk of heart attacks and strokes with long term use are projected to challenge the cyclooxygenase 2 inhibitor market in the forecast period of 2022-2029.
This cyclooxygenase 2 inhibitor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cyclooxygenase 2 inhibitor market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cyclooxygenase 2 inhibitor is associated with the cancers and abnormal growths in the intestinal tract. These inhibitors could be helpful in reducing the occurrence of cancers and pre-cancerous growths. Approximately, 19,292,789 new cancer cases were diagnosed throughout the world, according to the Globocan 2020 fact sheet. The global burden of cancers could reach the value of 27.5 million new cancer cases by 2040, according to estimates from the International Agency for Research on Cancer (IARC).
The cyclooxygenase 2 inhibitor market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cyclooxygenase 2 Inhibitor Market
A decline was witnessed in the diagnoses of cancer globally including, colorectal, lung, breast, esophageal pancreatic and gastric cancers. Centers for Disease Control and Prevention (CDC) along with numerous medical professional organizations recommended that cancer screening and other health prevention services to be postponed to secure the hospital infrastructure for the treatment of COVID-19 patients. The situation in the cyclooxygenase 2 inhibitor field is expected to gradually improve.
Global Cyclooxygenase 2 Inhibitor Market
The cyclooxygenase 2 inhibitor market is segmented on the basis of drug type, types, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
On the basis of drug type, the cyclooxygenase 2 inhibitor market is segmented into celecoxib, rofecoxib, valdecoxib, amlodipine and others.
- Selective cox 2 inhibitor
- Non-selective cox 2 inhibitor
On the basis of types, the cyclooxygenase 2 inhibitor market is segmented into selective cox 2 inhibitor and non-selective cox 2 inhibitor.
- Rheumatoid arthritis
On the basis of Indication, the cyclooxygenase 2 inhibitor market is segmented into osteoarthritis, rheumatoid arthritis and others.
Route of Administration
On the basis of route of administration, the cyclooxygenase 2 inhibitor market is segmented into oral, parenteral and others.
- Specialty Clinics
On the basis of end-users, the cyclooxygenase 2 inhibitor market is segmented into hospitals, specialty clinics and others.
- Hospital Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the cyclooxygenase 2 inhibitor market is segmented into hospital pharmacy, retail pharmacy and others.
Some of the cyclooxygenase 2 inhibitor (COX-2 inhibitors) are widely utilized in a single dose to treat pain after surgery. Etoricoxib is considered better than other pain medications, and Celecoxib appears to be about as useful as ibuprofen. Pfizer Inc., Bayer AG, Novartis AG, and Sabinsa, among others are some of the manufacturers involved with the development of cyclooxygenase 2 inhibitors.
Regulatory Framework: Cyclooxygenase 2 Inhibitor Market
The only cyclooxygenase 2 inhibitor available in the U.S is Celecoxib, following the withdrawal of rofecoxib in 2004. Valdecoxib was also taken off the market owing to the excessive increase in the risk of heart attack and stroke. However, FDA has approved Celebrex for treatment of familial adenomatous polyposis (FAP), and cyclooxygenase 2 inhibitors are being beneficial in the breast cancer studies.
Cyclooxygenase 2 Inhibitor Market Regional Analysis/Insights
The cyclooxygenase 2 inhibitor market is analysed and market size insights and trends are provided by country, drug type, types, indication, route of administration, end-users and distribution channel as referenced above.
The countries covered in the cyclooxygenase 2 inhibitor market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cyclooxygenase 2 inhibitor market due to the increased awareness and increase in studies associated with cancer within the region.
Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the surge in research and development activities in the region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Cyclooxygenase 2 Inhibitor Market Share Analysis
The cyclooxygenase 2 inhibitor market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cyclooxygenase 2 inhibitor market.
Some of the major players operating in the cyclooxygenase 2 inhibitor market are Pfizer Inc., Bayer AG, Novartis AG, Sabinsa, Cadila Pharmaceuticals., Mylan N.V., Teva Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aurobindo Pharma, Cipla Inc., Torrent Pharmaceuticals Ltd. and others.